Compare NUS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | CABA |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 319.6M |
| IPO Year | 1996 | 2019 |
| Metric | NUS | CABA |
|---|---|---|
| Price | $7.23 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 365.3K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | 10.26 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $3,176,718,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $2.30 | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $5.63 | $1.11 |
| 52 Week High | $14.62 | $3.78 |
| Indicator | NUS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 46.28 |
| Support Level | $7.03 | $2.32 |
| Resistance Level | $8.08 | $3.34 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 11.86 | 25.75 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.